FY2025 · ended Dec 31, 2025 · Revenue $418.63M, +20.0% YoY · Filed Feb 25, 2026
Mimedx Group, Inc. (MDXG) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $418.6 million and net income of $48.6 million. As of Sep 30, 2026 it held $120.8 million in cash and investments and $0 in total debt.
Revenue (TTM)
$303.73M
-22.8% vs year-ago TTM
Net income (TTM)
$-19.19M
-147.0% vs year-ago TTM
Operating cash flow (TTM)
$20.74M
-69.4% vs year-ago TTM
Free cash flow
$24.79M
EPS (TTM)
$-0.13
-147.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
148.57M
+0.8% vs prior year
Net cash
$120.79M
as of Sep 30, 2026
Operating margin
-8.3%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- MDXG (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Marietta, GA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1376339
- Former names
- Alynx, Co. (until Apr 2, 2008)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $418.6M | $348.9M | $321.5M | $267.8M | $242.0M |
| Operating income | $63.9M | $58.9M | $37.1M | -$14.7M | -$7.1M |
| Net income | $48.6M | $42.4M | $58.2M | -$30.2M | -$10.3M |
| Diluted EPS | $0.32 | $0.28 | $0.37 | -$0.33 | -$0.15 |
| Operating cash flow | $74.0M | $66.2M | $26.8M | -$17.9M | -$2.0M |
| Free cash flow | — | — | $24.8M | — | — |
| Total assets | $342.7M | $263.9M | $239.0M | $171.4M | $187.9M |
| Total liabilities | $86.1M | $70.8M | $96.3M | $96.9M | $95.4M |
| Stockholders' equity | $256.5M | $193.1M | $142.7M | -$18.0M | $82,000 |
| Cash and investments | $166.1M | $104.4M | $82.0M | $66.0M | $87.1M |
| Total debt | $22.6M | $25.0M | $52.4M | $53.9M | $55.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 16, 2026 | Oct 15, 2026 |
| 8-K/A |
Amended current report
Material agreement, Regulation FD disclosure
|
Aug 11, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 29, 2026 | Jul 29, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
All 1000 Mimedx Group, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.